clasornoflast

Clasornoflast (also known as RG6434 or RO7568282) is an investigational, oral, CNS-penetrant small-molecule inhibitor of the NLRP3 (NACHT, LRR and PYD domains-containing protein 3) inflammasome. Developed by Roche and its subsidiary Genentech, clasornoflast is designed to target neuroinflammation, which is a key driver of pathology in neurodegenerative disorders. By selectively inhibiting NLRP3, the drug prevents the assembly of the inflammasome complex, thereby reducing the activation of caspase-1 and the subsequent maturation and secretion of pro-inflammatory cytokines such as interleukin-1β (IL-1β) and interleukin-18 (IL-18). Clasornoflast is currently in Phase II clinical development for the treatment of early symptomatic Alzheimer's disease (in the TARBELA-AD trial) and early-stage Parkinson's disease (in the TARBELA-PD trial).